))
Episode 18: Antibiotic Resistance: Investing in the Next Generation of Antibiotics
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on February 27, 2024 04:28 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 337444516 series 3381207
Sisällön tarjoaa Gunnar Esiason. Gunnar Esiason tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
The State of Health continues the Antibiotic Resistance series with an episode featuring Henry Skinner, the CEO of the AMR Action Fund, a novel kind of investment fund that aims to catalyze the innovation ecosystem for novel antibiotics. Gunnar and Henry talk about the challenges of bringing new antibiotics to market, the difference between the AMR Action Fund and a traditional Biotechnology VC, and the pharmaceutical industry's role in tackling antibiotic resistance. The conversation turns to emerging antibacterial technologies, antibiotic market dynamics and what success means for the AMR Action Fund in the long term.
Earlier episodes in the Antibiotic Resistance Series are in the show's feed!
To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy
Learn more about your ad choices. Visit https://podcastchoices.com/adchoices
23 jaksoa
Jaa
